WO2010149658A3 - Pharmaceutical composition comprising gamma - butyrobetaine and meldonium - Google Patents

Pharmaceutical composition comprising gamma - butyrobetaine and meldonium Download PDF

Info

Publication number
WO2010149658A3
WO2010149658A3 PCT/EP2010/058824 EP2010058824W WO2010149658A3 WO 2010149658 A3 WO2010149658 A3 WO 2010149658A3 EP 2010058824 W EP2010058824 W EP 2010058824W WO 2010149658 A3 WO2010149658 A3 WO 2010149658A3
Authority
WO
WIPO (PCT)
Prior art keywords
butyrobetaine
gamma
pharmaceutical composition
meldonium
atherosclerosis
Prior art date
Application number
PCT/EP2010/058824
Other languages
French (fr)
Other versions
WO2010149658A2 (en
Inventor
Ivars Kalvins
Anatolijs Birmans
Maris Veveris
Antons Lebedevs
Anatolijs Misnovs
Original Assignee
Grindeks, A Joint Stock Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks, A Joint Stock Company filed Critical Grindeks, A Joint Stock Company
Publication of WO2010149658A2 publication Critical patent/WO2010149658A2/en
Publication of WO2010149658A3 publication Critical patent/WO2010149658A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Pharmaceutical composition of gamma-butyrobetaine and Meldonium dihydrate and its use in prevention and/or treatment of atherosclerosis and/or neurological diseases.
PCT/EP2010/058824 2009-06-25 2010-06-22 Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt WO2010149658A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-09-115 2009-06-25
LVP-09-115A LV14274B (en) 2009-06-25 2009-06-25 Combination medicinal product comprising meldonium

Publications (2)

Publication Number Publication Date
WO2010149658A2 WO2010149658A2 (en) 2010-12-29
WO2010149658A3 true WO2010149658A3 (en) 2011-03-31

Family

ID=42735612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/058824 WO2010149658A2 (en) 2009-06-25 2010-06-22 Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt

Country Status (2)

Country Link
LV (1) LV14274B (en)
WO (1) WO2010149658A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV14848B (en) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Pharmaceutical composition for lowering the level of trimethylamin-n-oxide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006794A1 (en) * 1995-08-21 1997-02-27 Ivars Kalvinsh Pharmaceutical composition for treating cardiovascular diseases containing 3-(2,2,2-trimethylhydrazinium) propionate and gamma-butyrobetaine
EP1103259A1 (en) * 1999-11-25 2001-05-30 Basf Aktiengesellschaft Use of y-butyrobetaine salts for the preparation of compositions suitable for human or animal nutrition
WO2005012233A1 (en) * 2003-08-04 2005-02-10 'joint Stock Company Grindeks' Meldonium salts, method of their preparation and pharmaceutical composition on their basis
RU2005125660A (en) * 2005-08-05 2007-02-20 Денис В чеславович Лисицын (RU) PHARMACEUTICAL COMPOSITION 3- (2,2,2-TRIMETHYLHYDRAZINY) PROPIONATE DIHYDRATE (MILDRONATE) AND SUITIC ACID SALTS
US20080279967A1 (en) * 2007-05-10 2008-11-13 Marvin Heuer Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006794A1 (en) * 1995-08-21 1997-02-27 Ivars Kalvinsh Pharmaceutical composition for treating cardiovascular diseases containing 3-(2,2,2-trimethylhydrazinium) propionate and gamma-butyrobetaine
EP1103259A1 (en) * 1999-11-25 2001-05-30 Basf Aktiengesellschaft Use of y-butyrobetaine salts for the preparation of compositions suitable for human or animal nutrition
WO2005012233A1 (en) * 2003-08-04 2005-02-10 'joint Stock Company Grindeks' Meldonium salts, method of their preparation and pharmaceutical composition on their basis
RU2005125660A (en) * 2005-08-05 2007-02-20 Денис В чеславович Лисицын (RU) PHARMACEUTICAL COMPOSITION 3- (2,2,2-TRIMETHYLHYDRAZINY) PROPIONATE DIHYDRATE (MILDRONATE) AND SUITIC ACID SALTS
US20080279967A1 (en) * 2007-05-10 2008-11-13 Marvin Heuer Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 2003 (2003-07-01), DZIAK L A ET AL: "[Use of mildronate for the treatment of patients with circulatory encephalopathy against a background of stenosis of major arteries of the head]", XP002602048, Database accession no. NLM14618818 *
LIKARS'KA SPRAVA / MINISTERSTVO OKHORONY ZDOROV'IA UKRAÏNY 2003 JUL-AUG LNKD- PUBMED:14618818, no. 5-6, July 2003 (2003-07-01), pages 98 - 101, ISSN: 1019-5297 *
OKUNEVICH I V ET AL: "Anti-atherosclerotic action of mildronate in experiment", PATOLOGICHESKAYA FIZIOLOGIYA I EKSPERIMENTALNAYA TERAPIYA, IZDATELSTVO MEDITSINA, RU, no. 2, 1 April 2002 (2002-04-01), pages 24 - 27, XP008087617, ISSN: 0031-2991 *
SJAKSTE N ET AL: "Mildronate: an antiischemic drug for neurological indications", CNS DRUG REVIEWS, BRANFORD, CT, US, vol. 11, no. 2, 1 July 2005 (2005-07-01), pages 151 - 168, XP002538538, ISSN: 1080-563X *

Also Published As

Publication number Publication date
LV14274B (en) 2011-03-20
LV14274A (en) 2011-01-20
WO2010149658A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
HRP20190059T1 (en) Compositions for the treatment of pain and/or inflammation
EP2099449A4 (en) Pharmaceutical composition for the treatment and prevention of diseases involving impotence
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
EP2125855A4 (en) Methods and compositions for the treatment of cancer or other diseases
IL207713A0 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
IL210916A (en) Clonidine and pharmaceutical composition comprising it for the prevention or treatment of an inflammatory disease in the mucosa
IL206296A (en) Aminopyrazole derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for prevention or treatment of diseases
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
ZA200905101B (en) Diagosis and treatment of preeclampsia
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
EP2079526A4 (en) Compositions and uses thereof in the treatment of wounds
EP2217238A4 (en) Methods and compositions for the treatment of proteinuric diseases
EP2206714A4 (en) Agent for prevention and/or treatment of skin diseases
EP2040726A4 (en) Trachelospermi caulis extract composition for the treatment and prevention of inflammatory diseases
HK1171677A1 (en) Composition for the treatment of hemorrhoids and related diseases
IL194880A (en) Aminothiazole derivatives, their use in the treatment of diseases and pharmaceutical compositions comprising them
EP2001488A4 (en) Prevention and treatment of cancer and other diseases
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
HRP20151393T8 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
EP2222295A4 (en) Pharmaceutical composition for treatment and prevention of kidney diseases
WO2010149658A3 (en) Pharmaceutical composition comprising gamma - butyrobetaine and meldonium
EP2441452A4 (en) Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals
PL387584A1 (en) Application of kynurenic acid and its derivatives in preventing or treatment of pancreas diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10737299

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10737299

Country of ref document: EP

Kind code of ref document: A2